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Introduction: Superiority of camptothecin regimens over etoposide—
both combined with platinum analogs—in extensive disease small cell
lung cancer has been a matter of debate with contradictory findings in
randomized trials. A systematic review was sought to elucidate this issue.
Methods: Randomized controlled trials comparing first-line camp-
tothecin-platinum doublets versus etoposide-platinum doublets in
patients with extensive disease small cell lung cancer were searched
in MEDLINE, EMBASE, LILACS, and CENTRAL databases, Eu-
ropean Society of Medical Oncology, American Society of Clinical
Oncology, and International Association for the Study of Lung
Cancer meeting sites. Meta-analyses were performed using fixed-
effects model. Subgroup analyses were undertaken comparing each
type of camptothecin to etoposide-based regimens. The outcomes of
interest were overall survival (OS), progression-free survival (PFS),
response rate (RR), and toxicities.
Results: Eight studies (3086 patients) were included. The meta-
analysis of topotecan regimens (TP) was not reliable due to impend-
ing heterogeneity. Meta-analysis of trials testing irinotecan combi-
nations (IP) versus etoposide regimens (EP; 1561 patients) stated an
OS improvement in favor of IP arm, though with considerable
heterogeneity, whose origin seemed to be a Japanese trial. In the
analyses without that study (1407 patients left), IP brought a signif-
icant improvement in OS (hazard ratio  0.87; 95% confidence
interval 0.78–0.97; p 0.02; I2 0). IP also increased PFS (hazard
ratio  0.83; 95% confidence interval 0.73–0.95; p  0.006; I2 
0%). There was no impact in RR (absolute RR 56% with IP; 53%
with EP; p  0.17). IP caused more diarrhea (p  0.0001) but less
hematological toxicities (p  0.001) than EP.
Conclusions: The present meta-analysis demonstrates statistically
significant OS and PFS benefits of IP over EP regimens in western
and eastern patients. Specific characteristics of safety profile should
be taken into account when administrating IP chemotherapy.
Key Words: Antineoplastic agents, Drug therapy, Lung neoplasms,
Meta-analysis, Small-cell lung carcinoma.
(J Thorac Oncol. 2010;5: 1986–1993)
Lung cancer is the leading cause of cancer-related mortalityin the world, accounting for more than 1,200,000 deaths
annually. Small cell lung cancer (SCLC) represents 15% of
all lung cancers and is one of the most aggressive types of
cancer with fast growth and early metastatic spread profile.1,2
Approximately two thirds of patients with SCLC are diag-
nosed with extensive-staged disease (extensive disease small
cell lung cancer [ED-SCLC]).3
The ED-SCLC is highly sensitive to chemotherapy with
response rates (RRs) reaching 80%.4 Nevertheless, these re-
sponses are of short duration, and most of patients die due to the
disease within 2 years. Nowadays, chemotherapy is being used
to provide palliation of symptoms and modest improvements in
survival with few patients achieving long-term survival.
For approximately 20 years, the combination of etoposide
with a platinum compound have been the standard treatment of
ED-SCLC.5 Different combinations using new generation drugs,
such as paclitaxel and gemcitabine, were tested in phase II trials
and demonstrated interesting RRs, ranging from 57 to 74%.6,7
Nevertheless, comparisons of those new regimens with etopo-
side-based regimens in phase III trials have shown disappointing
results in terms of survival.8–11
On the other hand, irinotecan has yielded some prom-
ising results.12–14 In a Japanese phase III trial, irinotecan
combined with cisplatin as first-line therapy in ED-SCLC
demonstrated striking results in terms of overall survival (OS)
and objective response, when compared with etoposide-cis-
platin.15 Despite this, randomized evaluations in western
patients have presented conflicting results.16,17 For these rea-
sons, current ED-SCLC guidelines reflect the uncertainty
about the exact role of irinotecan-based therapy.18,19 Addi-
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tionally, topotecan combined to cisplatin has also been tested
as first-line alternative against etoposide-cisplatin regimens.20
Camptothecins (irinotecan and topotecan) seem to play
a significant role in the management of SCLC. Nevertheless,
the importance of these drugs in first-line therapy is still
unclear despite all accumulated prospective data. To resolve
this question, we conducted a systematic review with meta-
analysis comparing camptothecin-platinum-based regimens
versus etoposide-platinum-based regimens in the first-line
therapy for patients with ED-SCLC.
METHODS
Search Strategy
A wide search of the main computerized databases was
conducted, including PubMed/MEDLINE, EMBASE, LILACS,
ClinicalTrials.gov, and CENTRAL. The ASCO, ESMO, and
IASLC Meeting websites were also scrutinized. We used a
sensitive search strategy, through words related to lung (lung
OR pulmonary*), cancer (carcinoma OR cancer OR neo-
plasms), chemotherapy (drug therapy OR chemotherapy*),
etoposide (etoposide OR VP), camptothecins (irinotecan OR
CPT-11 OR topotecan OR camptothecin), and randomized
trials (random*) in all fields. The search included literature
published or presented up to December 2009. All references
of relevant articles were scanned, and all additional studies of
potential interest were retrieved for further analysis. No
language restrictions were applied. Quorom guidelines were
followed.21
Selection Criteria
We sought to identify all published randomized con-
trolled clinical trials with a parallel design comparing etopo-
side-platinum versus camptothecin-platinum as first-line
treatment for ED-SCLC. Patients had to have histologic- or
cytologic-proven SCLC, evidence of extensive disease (dis-
ease extending beyond one hemithorax or pleural effusion),
and had to be chemonaive.
Two reviewers (J.P.S.N.L. and L.V.d.S.) analyzed the
list of references and independently selected the studies.
Data Extraction
The name of the first author and the year of publication
of the article were used for identification purposes. Two
reviewers (J.P.S.N.L. and L.V.d.S.) independently extracted
the data from all included studies. A third reviewer (A.D.S.)
was consulted to resolve disagreements.
The primary outcome analyzed was OS. Other points of
interest were progression-free survival (PFS), RR, and incidence
of Common Toxicity Criteria scale, grade 3/4 toxicities.
The hazard ratios (HRs) of time-to-event data (OS and
PFS) were directly extracted from the original studies or were
estimated indirectly using either the reported number of
events and the corresponding p value for the log-rank statis-
tics, or by reading off survival curves as suggested by Parmar
et al.22 The calculations were carried out using a spreadsheet
provided by Tierney et al.23 The number of events and
number under risk were abstracted for each dichotomous data
comparison evaluated.
Statistical Analysis and Synthesis
Details regarding the main methodological dimensions
empirically linked to bias as described by Sterne and cowork-
ers24 were extracted, and the methodological quality of each
selected trial were assessed by two reviewers. These data
were applied in a subgroup, and sensitivity analyses were
performed to test the stability of our conclusions.
All meta-analyses were performed using the Review
Manager 5 (RevMan 5; The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark) with the
fixed-effect model. Time-to-event outcomes were compared
using HR. Dichotomous data were compared using odds ratio
(OR). Respective 95% confidence intervals (CIs) were calcu-
lated for each estimate and presented in forest plots. The
pooled HR or OR, symbolized by a solid diamond at the
bottom of the forest plot (the width of which represents
the 95% CI), is the best estimate of the true (pooled) outcome.
The effect of the treatment for each single study was ex-
pressed as a ratio of camptothecin-based arm over the etopo-
side-based arm.
Statistical heterogeneity in the results of the trials was
assessed by the 2 test25 and was expressed as I2 index, as
described by Higgins et al.26 When a considerable heteroge-
neity was detected (I2  35%), a possible explanation for it
was pursued. When a reasonable cause was found, a separate
analysis was performed. If the cause was not apparent and
heterogeneity was caused by divergent data in terms of
direction of results (i.e., data favoring one or other treatment),
we chose not to pool the data. Publication bias was evaluated
by Egger’s test.24
Predefined subgroup analysis was done to access the
role on efficacy and safety of different camptothecins-based
regimens. Considering that the toxicity profiles of irinotecan
and topotecan are clearly divergent, these drugs were exam-
ined separately.27,28
RESULTS
Literature Search
The flow chart of the systematic search is summarized
in Figure 1. Nine potential eligible trials, published or pre-
sented between 2002 and 2009 were analyzed.2,15–17,20,29–32
One trial included patients with limited and extensive disease
and was, therefore, excluded.31 One trial reported safety and
RR results only, and these data were included in pertinent
analyses.29 None of the selected trials was a double-blinded
trial. Methodological details potentially related to bias are
described in Table 1.
Considering the eight selected studies, two studies were
carried out in the United States, four in Europe, one in Japan,
and one in China. Seven were reported in English, and one
was published in Chinese.
In six trials, cisplatin was the platinum compound
evaluated, and two studies used carboplatin.17,32 Six trials
used irinotecan in the experimental arm,2,15–17 and two com-
pared topotecan with etoposide regimens.20,33 Topotecan was
administered orally in one trial.20 Etoposide was administered
intravenously (IV) in all trials except one.17 The etoposide
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dose densities were similar, ranging between 100 and 140 mg
IV/m2/wk (mode dose density of 100 mg IV/m2/wk). Cispla-
tin dose densities were similar within trials but varied among
trials ranging from 15 to 25 mg/m2 IV wk. Carboplatin dose
densities ranged from 1.25 to 1.7 area under the curve/wk in
the two trials, which applied it as platinum compound. A
detailed description of treatment arms of all included studies
is presented in Table 2.
The postprogression treatments were described just in
three trials.16,17 These further therapies were left to discretion
of treating physicians.
Overall Survival
The impact of the camptothecin-based treatment on OS
was extracted directly or estimated indirectly from published
data of seven trials. A total of 3025 patients were analyzed.
Only two studies demonstrated statistically significant results,
favoring camptothecin-based chemotherapy.15,17
In the meta-analysis, the HR for OS favored camptoth-
ecin-based chemotherapy, although the interaction test showed
important difference between camptothecin subgroups (p 
0.04; Figure 2). This result indicates that there were significant
differences between irinotecan and topotecan regimens in terms
of efficacy, thus pooling these two camptothecins into same
analysis was considered inappropriate. Therefore, we evaluated
data from irinotecan and topotecan regimens separately. Funnel
plot graphic did not show evidence of significant publication
bias risk (Egger’s test p value  0.059).
Irinotecan-Based Versus Etoposide-Based
Chemotherapy
Pooling the data from the irinotecan-based chemother-
apy trials was associated with moderate heterogeneity (I2 
45%). The assessment of the meta-analysis indicated that the
trial by Noda et al.15 could be the source of the heterogeneity.
This trial was the only one that exclusively included Japanese
population and was terminated early due to positive findings
in an interim analysis, with less than two thirds of pro-
grammed accrual. Some ethnical pharmacogenomic peculiar-
ities between western and Japanese patients have been advo-
cated to play a role in irinotecan metabolism and activity and
could justify the heterogeneity between trials.
Analyzing the four western trials that reported OS data
(1407 patients left), irinotecan-based regimen provided sig-
nificant OS benefit with 13% reduction in mortality with no
heterogeneity (HR 0.87; 95% CI: 0.78–0.97; p 0.02; I2 
0%; p  0.23; Figure 3). Considering the average OS of
patients with ED-SCLC treated with etoposide-based therapy
lies between 8 and 10 months, the theoretical improvement
brought by irinotecan would be near to one to two additional
months of OS.
Topotecan-Based Versus Etoposide-Based
Chemotherapy
Meta-analysis of topotecan-based chemotherapy (1464
patients enrolled in two trials) did not show any gain in terms
of OS (HR 0.99; 95% CI: 0.88–1.11; p 0.87). There was
no evident heterogeneity in this analysis (p 0.31; I2 5%).
Progression-Free Survival
Information concerning PFS was available in six trials.
Thus, PFS analysis was based on data extracted from the two
topotecan versus etoposide trials and four of irinotecan versus
etoposide trials.
Irinotecan-Based Versus Etoposide-Based
Chemotherapy
Combination of data from four irinotecan versus eto-
poside trials reporting PFS2,15,16,32 also presented significant
heterogeneity (I2  63%; p  0.04). Taking in account that
the Japanese trial was a source of heterogeneity in OS analysis,
this study was also excluded from PFS analysis.15 This approach
left under analysis only western trials and caused a partial
reduction in heterogeneity (I2  49%; p  0.20). We sought
another source for the elevated heterogeneity.
One trial, conducted by Hanna et al., presented diver-
gent PFS results what seemed to be the source of residual
heterogeneity. This trial tested irinotecan-cisplatin versus
etoposide-cisplatin in similar dose-densities of all other trials.
No methodological flaws could be found. We proceeded with
the exclusion of this trial from analysis. Nevertheless, once
we could not identify any clear reasons to exclude the trial by
Hanna et al. from analysis, the PFS results presented must be
interpreted as exploratory, and no definitive conclusions can
be drawn. In this scenario (two studies, 867 patients left),
irinotecan-based chemotherapy improved PFS with statistical
significance and no detectable heterogeneity (HR  0.83;
95% CI: 0.73–0.95; I2  0; Figure 4).
Topotecan-Based Versus Etoposide-Based
Chemotherapy
The studies comparing topotecan to etoposide regimens
were clearly conflicting: both studies had positive findings,
FIGURE 1. Flow chart of the systematic review. LD-SCLC,
limited-stage small cell lung cancer; RCT, randomized con-
trolled trial; SCLC, small cell lung cancer.
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one favoring topotecan-based regimen30 and the other etopo-
side-based regimen.20 These divergent results, as expected,
caused an unacceptable high heterogeneity (I2  90%) pre-
venting a valid combined analysis.
Response Rate
Information concerning RR was available in the seven
trials.2,15,16,20,29,30,32 Therefore, RR analysis was based on data
extracted from the two topotecan versus etoposide trials20,30 and
five of irinotecan versus etoposide trials.2,15,16,29 Responses were
assessed according to the WHO criteria in the trial by Pan
et al.29,32 and RECIST in the study by Schmittel et al.32 No other
trial clearly stated the evaluation criteria applied.
Irinotecan-Based Versus Etoposide-Based
Chemotherapy
Irinotecan-based versus etoposide-based regimens
(1317 patients) analysis was feasible with acceptable hetero-
geneity (I2  30%; p  0.25). Meta-analysis showed a
TABLE 1. Characteristics of Included Studies
Author Year Random Allocation Withdrawn Descript Alpha Error Beta Error ITT Placebo Multicentric Sponsor
Eckardt et al.20 2006 Unclear Unclear Yes Yes Yes Yes No Yes Industry
Hanna et al.16 2006 Yes Yes No Yes Yes Yes No Yes Industry
Heigener et al.30 2008 Unclear Unclear Yes Yes Yes Yes No Yes Industry
Hermes et al.17 2008 Yes Yes Yes Yes Yes Yes No Yes Both
Lara et al.2 2009 Unclear Unclear Unclear Yes Yes Yes No Yes Academic
Noda et al.15 2002 Yes Yes Yes Yes Yes Yes No Yes Academic
Pan et al.29 2006 Yes Yes No Yes No No No No Unclear
Schmittel et al.32 2009 Yes Unclear Yes Yes Yes Yes No Yes Unclear
Both, pharmaceutical and academic sponsorship; ITT, intention-to-treat analysis; random, randomization.
TABLE 2. Description of Treatments Arms in the Included Trials
Trial
Camptothecin Arm Etoposide Arm
N Age Doses N Age Doses
Eckardt et al.20 389 60 CDDP 60 mg/m2 IV d1  395 60 CDDP 80 mg/m2 IV d1 
Topo 1.7 mg/m2 PO d1–5 VP-16 100 mg/m2 IV d1–3
Every 3 wk for 4 cycles Every 3 wk for 4 cycles
Hanna et al.16 219 63 CDDP 30 mg/m2 IV d1, and d8  109 62 CDDP 60 mg/m2 IV d1 
CPT-11 65 mg/m2 IV d1, and d8 VP-16 120 mg/m2 IV d1–3
Every 3 wk for 4 cycles Every 3 wk for 4 cycles
Heigener et al.30 346 61 CDDP 75 mg/m2 IV d1  334 61 CDDP 75 mg/m2 IV d5 
Topo 1 mg/m2 IV d1–d5 VP-16 100 mg/m2 IV d1–3
Every 3 wk for 4 cycles Every 3 wk for 4 cycles
Hermes et al.17 105 67 Carboplatin AUCa 4 IV d1  104 68 Carboplatin AUCa 4 IV d1 
CPT-11 175 mg/m2 IV d1 VP-16 120 mg/m2 PO d1–5
Every 3 wk for 4 cyclesb Every 3 wk for 4 cyclesb
Lara et al.2 324 62 CDDP 60 mg/m2 IV d1  327 63 CDDP 80 mg/m2 IV d1 
CPT-11 60 mg/m2 IV d1, d8, and d15 VP-16 100 mg/m2 IV d1–3
Every 4 wk for 4 cycles Every 3 wk for 4 cycles
Noda et al.15 77 63 CDDP 60 mg/m2 IV d1  77 63 CDDP 80 mg/m2 IV d1 
CPT-11 60 mg/m2 IV d1, d8, and d15 VP-16 100 mg/m2 IV d1–3
Every 4 wk for 4 cycles Every 3 wk for 4 cycles
Pan et al.29 30 54 CDDP 26.6 mg/m2 IV d1–3  31 51 CDDP 26.6 mg/m2 IV d1–3 
CPT-11 80 mg/m2 IV d1, d8, and d15 VP-16 120 mg/m2 IV d1, d8, and d15
Every 4 wk for 4 cycles Every 3 wk for 4 cycles
Schmittel et al.32 106 60 Carboplatin AUCc 5 IV d1  110 63 Carboplatin AUCc 5 IV d1 
CPT-11 50 mg/m2 IV d1, d8, and d15 VP-16 140 mg/m2 IV d1–3
Every 4 wk for 6 cycles Every 3 wk for 6 cycles
Chatelut AUC4 (as used by Hermes et al.) is almost identical to Calvert AUC5 as used by Schmittel et al.
a Area under the curve by Chatelut’s Formula.
b Dose reduction of 33% for patients older than 70 yr or PS 2.
cArea under the curve by Calvert’s Formula.
N, number of patients enrolled in each arm of study; age, median age; CDDP, cisplatin; CPT-11, irinotecan; VP-16, etoposide; Topo, topotecan; IV, intravenously; PO, orally; PS,
performance status.
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significant difference in RRs between irinotecan-based and
etoposide-based regimens favoring irinotecan therapy. Nev-
ertheless, in robust analysis, the trial by Noda et al. was the
main source of that apparent gain. Excluding the Japanese
study,15 this gain disappeared (RR  1.18; 95% CI: 0.93–
1.49; p  0.17). The absolute RRs among the evaluable
population were 56% for irinotecan-based and 53% for eto-
poside-based regimens (Figure 5).
Topotecan-Based Versus Etoposide-Based
Chemotherapy
Similarly to PFS analysis, the two topotecan versus
etoposide trials provided divergent results, and again, no
valid conclusion could be drawn. Meta-analysis was not
performed.
Toxicity
Irinotecan-Based Versus Etoposide-Based
Chemotherapy
All studies described some sort of toxicities; however,
only diarrhea, anemia, and thrombocytopenia data were con-
stantly described in the publications. Patients treated with
irinotecan were less likely to experience hematological tox-
icities but more susceptible to suffer severe diarrhea. Toxic-
ity-related deaths were described in three trials (35 deaths,
963 patients),2,15,32 with no identifiable difference between IP
and EP (OR  1.08; 95% CI: 0.55–2.13; p  0.50; I2  0).
Data of grades 3 to 4 toxicities are summarized in Table 3
with respective numbers needed to harm. Heterogeneity was
numeric relevant in some comparisons, but there were no
FIGURE 2. Overall survival meta-analysis of camptothecin versus etoposide-based regimens.
FIGURE 3. Overall survival meta-analysis of irinotecan versus etoposide-based chemotherapy in western trials.
FIGURE 4. Progression-free survival meta-analysis of irinotecan versus etoposide-based chemotherapy in western patients.
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clinical divergent results among these comparisons in any
trial. Unfortunately, no direct comparisons of western versus
eastern patients could be done due to the lack of specific data.
Topotecan-Based Versus Etoposide-Based
Chemotherapy
There was an extensive description of toxicities in two
trials that compared topotecan with etoposide.20,30 All anal-
ysis of side effects resulted in important heterogeneity (I2
ranging from 20 to 99%) with divergent directions of benefit.
Careful examination of the phase III trial that directly com-
pare oral versus IV topotecan monotherapy in second-line
setting could suggest that, despite the similarity of toxicity
profiles, the frequency of specific adverse events may vary
according to the administration route.34 Therefore, we chose
not to poll these data.
DISCUSSION
The main result of the present meta-analysis is the
homogenous and significant OS improvement provided by
irinotecan-based chemotherapy, when compared with etopo-
side-based regimens.
Camptothecins and platinum analogs doublets showed
to be promising regimens in terms of improved response and
survival in previous prospective trials.35–38 The relevant in-
teraction test found between camptothecins in the present
meta-analysis originated from inherent differences of these
two drugs—irinotecan and topotecan.26 Pooling topotecan
studies with irinotecan-based ones seemed rational at first,
but the interaction test showed this would cause illegitimate
conclusions. The different toxicity profiles and activities of
these compounds clearly demonstrate that they are distinct
entities and must be analyzed separately.
The pooled OS data of all five irinotecan versus etopo-
side trials resulted in significant heterogeneity (I2  45%)
originated from Noda et al.15 Pooling exclusively the other
four studies, all including a majority of western patients (1407
patients left), decreased considerably heterogeneity (I2  0%),
caused little change in HR result, and also retained statistical
significance (p  0.02).
The Japanese study by Noda et al. was devoid of
identifiable methodological flaws as stated in Table 1 and
could be classified as a high-quality trial in the majority of
quality scales currently in use.24 Besides its early interrup-
tion—what could allow chance to influence results—the trial
by Noda et al. could be foreseen as a singular one because it
was the only one evaluating exclusively eastern patients with
mature OS data reported.
The justified concern about heterogeneity in meta-
analytical process occurs due to the fear of pooling data from
divergent studies, what may lead to inaccurate assumptions.
This does not seem to be the case in the present meta-analysis
as there were no discrepant results in the irinotecan versus
etoposide trials. Examining each irinotecan versus etoposide-
based trial separately, there was a trend of better OS in favor
of irinotecan-regimens—with or without statistical signifi-
cance—in all of them. In attempt to decrease heterogeneity,
the exclusion of the Japanese trial left under OS analysis only
western studies. Even after this exclusion, persists the clear
evidence of OS improvement with statistical significance
brought by irinotecan-based chemotherapy.
FIGURE 5. Overall response rate meta-analysis of irinotecan-based therapy trials.
TABLE 3. Grade 3 to Grade 4 Toxicities (CTC Scale) of Irinotecan-Based vs. Etoposide-Based
Regimens
Grade 3 to Grade 4 Toxicities No. of Patients OR (95% CI) p I2 (%) NNH
Diarrhea 1598 8.94 (5.30–15.07) 0.0001 40 7
Anemia 1598 0.52 (0.38–0.72) 0.0001 0 15
Leukopenia 1276 0.41 (0.32–0.53) 0.00001 62 6
Neutropenia 1176 0.20 (0.16–0.27) 0.00001 80 3
Neutropenic fever 538 0.43 (0.20–0.93) 0.03 0 26
Thrombocytopenia 1598 0.24 (0.17–0.34) 0.00001 0 7
An OR 1 favors irinotecan-based therapy, whereas an OR 1 favors etoposide-based therapy.
OR, odds ratio; CI, confidence interval; NNH, number needed to harm; CTC, Common Toxicity Criteria.
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We could only speculate the highly significant HR in
favor of irinotecan in the Japanese trial may be happened not
only due early closure but also due genomic differences
among eastern and western patients. In this study, there was
a strong perception of different efficacy of irinotecan among
ethnic groups. The trial by Noda et al. was an “excessively
favorable” trial among modestly positive trials, adding some
quantitative heterogeneity in comparisons undertaken, though
it was not divergent in its conclusions.2,39
In the present meta-analysis, the inclusion of a trial
using oral etoposide in the standard arm might have raised
concerns about efficacy of the standard comparator and re-
quired clarification. Similarity of oral and IV administration
routes came from comparative pharmacokinetics studies in
solid tumors where an oral dose of etoposide close to twice
the IV dose seemed to compensate the reduced intestinal
uptake.40,41 This compensation was repeated in the Hermes
trial, maintaining the dose intensity of IV etoposide used in
the other trials what granted the inclusion of this trial in the
analyses.
This review demonstrated that irinotecan regimens
were capable of improving OS and PFS but not RR. Notwith-
standing the positive results, PFS meta-analysis was limited
to just two trials after exclusion of trials by Noda et al. and
Hanna et al. The former one was excluded based on the
hypothesis of different genomic background. The exclusion
of last trial was merely based on statistical demands: it
enrolled western patients, used similar drug dose-densities
and had no methodological flaw as the other two trials which
remained in PFS analysis.
We acknowledge that the present meta-analysis PFS
results must not be seen as definitive. Until the present, no
prospective data about PFS ability in predicting OS gains
have been published. Nevertheless, our results pose concern
about any eventual PFS surrogacy and indicate that RR may
not be a strong surrogate for OS.42 Hypothetically, the portion
of included patients with nonmeasurable disease might un-
derscore RR and PFS evaluations. These facts highlight the
care we must take to avoid overestimating the importance of
these two secondary endpoints in clinical practice.
Data of topotecan-based regimens have a more difficult
interpretation. After a thorough search, we found only two trials
that restricted randomization to patients with ED-SCLC. Pooling
just two trials increased the risk of excessive heterogeneity what
may lead to illegitimate inferences.26 Additionally, we consid-
ered that there was another potential cause for such heterogene-
ity in the topotecan analysis.
The direct comparison of oral versus IV topotecan in
ED-SCLC was performed in only one monotherapy study in
second-line setting.34 It was a noninferiority trial in terms of
RR, and no formal statistical evaluation of PFS or OS was
planned. ORR and OS were similar among arms, but PFS
analysis showed a nonstatistical significant trend in favor of
IV use (HR: 1.23; 95% CI: 0.98–1.55; data abstracted ac-
cording to Parmar et al.,22 not shown). Also, the toxicity
profile seemed to change according to administration route.
Even considering these results in the second-line setting and
PFS as an invalid OS surrogate, this trial raises uncertainty
about interchangeability of IV and oral topotecan efficacies.
Until the present date, topotecan therapy should be reserved
to the second-line therapy in SCLC.
The toxicities found were compatible with expected
drug profiles. Hematological side effects were consistently
more common among etoposide-treated patients in all trials.
Diarrhea, a typical drug class toxicity, was considerably more
present in irinotecan-exposed patients. Unfortunately, evalu-
ation of other important toxicities such as febrile neutropenia,
drug-related death, nausea, and dehydratation were not fea-
sible due to the scarcity of reported data. The concerns about
ethnic differences in terms of frequency and intensity of toxic
effects remain unanswered because there was just one indi-
rect comparison of western versus eastern patients available
at the time of this review.33
This study has the typical limitations of the meta-
analytical methodology. Our findings and interpretations
were limited by the quality and quantity of data available.
Additionally, only presented or published data were used in
this meta-analysis. Another source of bias is the possible
existence of some unpublished studies, which could lead to
potential publication bias. We found no indication of such
bias by using statistical methods designed to detect it. An
analysis of individual patient data would be more powerful to
confirm our findings.
Another meta-analysis recently published also com-
pared irinotecan regimens versus etoposide regimens in
ED-SCLC.43 In that article, Yao et al polled three trials in
OS analysis and did not identify any benefit of irinotecan over
etoposide in 1- and 2-year survival rates. The discrepancy
between this study and Yao et al. might rise due to different
methodological aspects of these two meta-analyses. Yao et al.
polled a reduced number of studies and opted to use tipping
points for OS far from the historical median survival. These
two aspects of Yao et al. meta-analyses might compromise
their ability in identifying small, but clinically relevant,
differences.
In conclusion, this systematic review indicated that
irinotecan-platinum chemotherapy provides superior OS
compared with etoposide-platinum regimens for patients with
ED-SCLC with a theoretical gain of 1 month in median OS.
The toxicity profile of irinotecan should be taken in account
when proposing it as first-line therapy for ED-SCLC. Irino-
tecan combined with platinum should be strongly considered
as a standard first-line treatment for patients with ED-SCLC.
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